Saw palmetto fruit extract improves LUTS in type ⅢA prostatitis patients.
- Author:
Yun-Peng SHAO
1
;
Hao-Liang XUE
1
;
Bai-Xin SHEN
1
;
Liu-Cheng DING
1
;
Zheng-Seng CHEN
1
;
Zhong-Qing WEI
1
Author Information
1. Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China.
- Publication Type:Journal Article
- Keywords:
low urinary tract symptoms;
saw palmetto fruit extract;
urodynamic examination;
ⅢA prostatitis
- MeSH:
Adult;
Chronic Disease;
Humans;
Lower Urinary Tract Symptoms;
drug therapy;
etiology;
Male;
Plant Extracts;
therapeutic use;
Prostatitis;
complications;
Quality of Life;
Retrospective Studies;
Treatment Outcome;
Urination;
Urological Agents;
therapeutic use
- From:
National Journal of Andrology
2017;23(5):417-421
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the clinical efficacy of the saw palmetto fruit extract (SPFE) in the treatment of lower urinary tract symptoms (LUTS) in patients with type ⅢA prostatitis.
METHODS:This retrospective study included 54 cases of type ⅢA prostatitis treated in the Outpatient Department of our hospital from January to December 2015. The patients were aged 35.06 ± 5.85 years, with a mean disease course of 3.8 ± 2.1 years, and all received oral medication of SPFE Capsules at the dose of 320 mg qd for 12 weeks. We assessed the therapeutic effects by comparing the NIH-chronic prostatitis symptom indexes (NIH-CPSI), voiding diary, International Prostate Symptom Scores (IPSS), and results of urodynamic examination before and after treatment.
RESULTS:Compared with the baseline, both NIH-CPSI and IPSS were significantly decreased after medication (27.61 ± 3.76 vs 18.6 ± 5.34, P <0.01; 20.44 ± 4.51 vs 10.96±4.62, P <0.01), and urodynamic examination and voiding diary showed dramatic post-medication improvement in the average urinary flow rate (［8.05±1.42］ vs ［12.05±2.60］ ml/s, P <0.01 ), maximum urinary flow rate (［14.22±1.74］ vs ［21.32±4.51］ ml/s, P <0.01), residual urine volume (［46.15±16.57］ vs ［14.55±10.21］ ml, P <0.01), maximum urethral closure pressure (［76.52±3.53］ vs ［65.32±4.75］ cm H2O, P <0.01), mean urinary volume (［124.63±40.55］ vs ［285.93±58.68］ ml, P <0.01), urination frequency (16.96±4.17 vs 8.96±2.50, P <0.01), and nocturia frequency (8.94±3.23 vs 3.15±1.90, P <0.01). No apparent adverse reactions were observed in any of the patients.
CONCLUSIONS:SPFE Capsules can safely and effectively improve LUTS and thus the quality of life of patients with type ⅢA prostatitis.
